Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865595 | 1.00 | AR (0.71) | ARPOLBGRM4HCAR1CYP1A2 | |
| SCHEMBL6211148 | 1.00 | AR (0.71) | ARPOLBGRM4HCAR1CYP1A2 | |
| SCHEMBL5865592 | 1.00 | AR (0.71) | ARPOLBGRM4HCAR1CYP1A2 | |
| SCHEMBL13964673 | 1.00 | AR (0.71) | ARPOLBGRM4HCAR1CYP1A2 | |
| SCHEMBL5865677 | 0.85 | AR (0.71) | AR | |
| SCHEMBL5865668 | 0.85 | AR (0.71) | AR | |
| SCHEMBL5865672 | 0.85 | AR (0.71) | AR | |
| SCHEMBL13964575 | 0.85 | AR (0.71) | AR | |
| SCHEMBL5865675 | 0.85 | AR (0.71) | AR | |
| SCHEMBL4040772 | 0.85 | AR (0.71) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | claimed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | claimed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | AR 43/4885POLB 2511/4885GRM4 128/4885 |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | AR 43/4885POLB 2511/4885GRM4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.